Investor Relations

Ron Ginor MD

Ron Ginor, MD specializes in guiding medical device companies through initial research and development, clinical study development and management, and ultimately, FDA approval and third party reimbursement. Dr. Ginor has been involved with technologies that span the medical device spectrum from coronary stent design to novel prostate cancer therapies.

Dr. Ginor has served as both a partner and a venture partner in life science focused venture capital funds and as a consultant to both the venture and investment banking community. In this capacity, he guides VC funds, investment banks and hedge funds in making life science investments and manages complex clinical and regulatory strategies, including FDA dispute resolution and expert panel meetings, on behalf of approximately 20 private and public life science companies. Companies led by Dr. Ginor have raised more than US $100 Million in VC funding and have reached more than US $1 Billion in market capitalization.

Dr. Ginor is a graduate of the Elliot School of International Affairs with a degree in International Economics and the George Washington University School of Medicine. Prior to leaving academic medicine in 1997, he worked on the development of conformal 3D radiation therapy modalities for prostate cancer treatment at The Memorial Sloan Kettering Cancer Center and on radio sensitizing drugs at Stanford University. He holds several US and International patents, and has published extensively in peer reviewed literature.